Beriplex P/N 500 1020 Unit (Coagulation Factor X (Human) POWDER FOR SOLUTION) 1020 UNIT

BERIPLEX P/N 500 1020 UNIT is a coagulation factor X (human) powder for solution, used for managing bleeding in certain medical conditions. This intravenous medication supports blood clotting and is manufactured by CSL Behring Canada Inc.

Strength

1020 UNIT

Pack Size

30ML

Manufacturer / TM Owner

CSL BEHRING CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

BERIPLEX P/N 500 1020 UNIT is primarily used to control bleeding in individuals with coagulation factor X deficiency. This medication is often administered in clinical settings to support blood clotting processes. It is important to consult healthcare professionals to determine the appropriate use of coagulation factor X (human) for specific conditions.

Side Effects

Common effects of BERIPLEX P/N 500 1020 UNIT may include localized reactions at the injection site, such as redness or swelling. Some individuals might experience mild allergic reactions. As with any medication, effects can vary, and it is essential to monitor for any adverse reactions.

Precautions & Warnings

BERIPLEX P/N 500 1020 UNIT should be handled with care, ensuring proper storage and preparation. It is crucial to follow healthcare provider instructions for administration. Individuals with known allergies to coagulation factor X or any components of the solution should avoid its use.

Avoid Interactions

BERIPLEX P/N 500 1020 UNIT may interact with other medications that affect blood clotting. It is important to inform healthcare providers about all current medications, including over-the-counter drugs and supplements, to avoid potential interactions. Alcohol consumption should also be discussed with a healthcare professional.

Frequently Asked Questions

BERIPLEX P/N 500 1020 UNIT is used to manage bleeding in individuals with coagulation factor X deficiency.

BERIPLEX P/N 500 1020 UNIT is administered intravenously as a solution prepared from the powder.

Common effects may include localized reactions at the injection site, such as redness or swelling.

Individuals with known allergies to coagulation factor X or any components of the solution should avoid its use.

Yes, it may interact with other medications that affect blood clotting, so it is important to consult a healthcare provider.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.